This effect may be associated with HDAC2 restoration via RORt/IL-17 pathway regulation, suggesting that CpG-ODNs are potential corticosteroid-sparing agents for use in CS-induced asthma with Th17-biased immune conditions. The gene discussed is IL17A; the disease is asthma.